Providers

I studied basic neuroscience at Leeds and UCL before undertaking a PhD at Imperial College.

During my doctoral studies, I developed an interest in studying the central regulation of energy and glucose homeostasis using in vivo imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET).

I subsequently held brief post-doctoral positions at the University of Oxford and MRC London Institute of Science before a lengthier stay at the BMBF- and DFG-funded obesity research centres in Leipzig University, Germany.

I am currently Lead Scientist at the Department of Experimental Surgery situated at the University of Wuerzburg where I am working on the mechanisms of weight loss after gastric bypass surgery using animal models. 

Professor Sikora is a British physician specialising in oncology. He is medical director of Rutherford Health, and Director of Medical Oncology at the Bahamas Cancer Centre. He is also Professor of Medicine at the University of Buckingham, and a partner in and dean of Buckingham's medical school.

Professor Sikora studied medical science and biochemistry at Cambridge, where he obtained a double first.

After clinical training he became a house physician at The Middlesex Hospital and registrar in oncology at St Bartholomew’s Hospital. He later became a research student at the MRC Laboratory for Molecular Biology in Cambridge working with Nobel Prize winner, Dr Sydney Brenner.

He obtained his PhD and became a clinical fellow at Stanford University, California before returning to direct the Ludwig Institute in Cambridge.

He has been Clinical Director for Cancer Services at Hammersmith for 12 years and established a major cancer research laboratory there funded by the Imperial Cancer Research Fund. He chaired Help Hammer Cancer, an appeal that raised £8m towards the construction of the new Cancer Centre at Hammersmith. He became Deputy Director (Clinical Research) of the ICRF.From 1997 to 1999 he was Chief of the WHO Cancer Program and from 1999 to 2002 and Vice President, Global Clinical Research (Oncology) at Pharmacia Corporation.

He has published over 300 papers and written or edited 20 books and is on the editorial board of several journals and is the founding editor of Gene Therapy and Cancer Strategy.

He was a member of the UK Health Department’s Expert Advisory Group on Cancer (the Calman-Hine Committee), the Committee on Safety of Medicines and remains an adviser to the WHO. He currently directs a cancer drug donation programme in Africa.

Asma Khalil is a Professor of Obstetrics and Maternal-Fetal Medicine at St George’s University Hospital (University of London). She is a subspecialist in Maternal and Fetal Medicine, specialising in scanning women and babies with complications in pregnancy. She is the lead for the Multiple Pregnancy service at St George’s Hospital, the referral unit for the South West London region, but also cares for women with low risk pregnancies.

Dr Khalil gained her MD at the University of London in 2009 following two years’ research into pre-eclampsia (high blood pressure in pregnancy). She also has a Masters degree in Epidemiology from the London School of Hygiene & Tropical Medicine and an MRC scholarship.

She is a representative member for fetal medicine at the national Clinical Reference Groups for specialised services. She has active collaborations with international societies, particularly in developing countries. She is also an active member of the Royal College of Obstetricians and Gynaecologists (RCOG), British Maternal and Fetal Medicine Society (BMFMS), International Society for Prenatal Diagnosis and Therapy (ISPD), International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), International Society for the Study of Hypertension in Pregnancy (ISSHP) and Society of Reproductive Investigation (SRI). She works closely with the team in the Twins and Multiple Births Association (TAMBA).

Mr Christopher Anderson is a consultant urological surgeon with a specialist interest in renal and prostate cancer. He is the Clinical Lead of the Robotic Surgery Unit and the Lead Cancer Clinician at St George's Hospital, London.

Mr Anderson was one of the pioneers of Robotic Surgery in the UK and holds membership at the British Association for Urological Surgeons. He completed his undergraduate work at Stellenbosch and his postgraduate training in Cape Town, South Africa, before taking up a substantive consultant post at St George’s Healthcare, London, in 1999. He undertook fellowships to Cleveland, the University of Miami and Detroit in the United States before travelling to the University of Leipzig in Germany where he learned laparoscopic radical prostatectomy due to the increasing popularity of minimally invasive surgical approaches to prostate cancer in recent years.

Mr Anderson was one of the first to adopt laparoscopic techniques in urology surgery in the UK. In 2004 he introduced laparoscopic renal cryotherapy, also the first operation of its kind in the UK. He continued to develop this technique and has the largest series with long term follow-up in the country.

He was an integral member of the team that pioneered robotic surgery in the UK, introducing the robotic surgery programme to St George’s Healthcare in July 2008, and has successfully developed the service as lead robotic surgeon.

His particular clinical interests include robotic prostatectomy, robotic partial nephrectomy, robotic pyeloplasty and laparoscopic nephrectomy. Mr Anderson is available for private consultations at The Princess Grace Hospital, London.

Dr Sufyan Hussain is Consultant Physician in Diabetes and Endocrinology at Guy's and St Thomas' NHS Foundation Trust, London, Honorary Senior Clinical Lecturer at King's College London and Honorary Clinical Lecturer in Diabetes, Endocrinology and Metabolism at Imperial College Healthcare NHS Trust and Imperial College London.

A former Wellcome Trust Clinical Research Fellow And Darzi Fellow in Clinical Leader ship at Imperial College London, Dr Hussain completed his medical degree and MA in molecular sciences from the University of Cambridge. He served as a Visiting Research Fellow at Joslin Diabetes Center, Harvard Medical School.

He completed a PhD in neuroendocrinology investigating how the brain controls appetite and blood glucose.

John Green is a leading internationally recognised oncologist specializing in gynaecologic and ovarian cancers.

Professor Mike Loosemore is Lead Consultant in Sport and Exercise Medicine at the Institute of Sport, Exercise and Health. He treats the general public with musculoskeletal and sports injuries and is also working to promote exercise as a preventative intervention and treatment in many medical conditions.

Professor Loosemore is a Lead Sports Physician for the English Institute of Sport, based at ISEH where he treats elite athletes from a wide range of sports; he is currently the Chief Medical Officer for GB Boxing and GB Snow sports.

He has travelled extensively with national squads, accompanying teams to 4 Olympic and 5 Commonwealth Games, World and European Championships. He was the Chief Medical Officer (CMO) for the England Commonwealth Games team in New Delhi 2010 and reprised the role for Glasgow 2014. He was CMO for the GB team at the 2018 Winter Olympics.

Professor Loosemore is active in various fields of sport and exercise medicine research and has published work on various aspects of Sports and Exercise Medicine.

In 2011 he was awarded an honorary doctorate in science for ‘outstanding contribution to sport and exercise medicine’. In 2014 he received the Sir Robert Atkins award for ‘an outstanding contribution to sports medicine’.

He was awarded an MBE for services to Sport and Exercise Medicine in 2018.

Professor Gabra is Co-Founder, Board Member and Chief Scientific Officer at Papyrus Therapeutics Inc; he also hold the position of Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust and is Professor Emeritus in Medical Oncology, Imperial College London.

He has extensive experience of preclinical cancer biology and clinical drug development, having previously been Chief Medical Officer at BerGenBio,Oxford, UK and Vice President in Early Clinical Development at AstraZeneca in Cambridge, UK, concurrently holding the positions of Professor of Medical Oncology at Imperial College London and Honorary Consultant in Medical Oncology at Imperial College Healthcare NHS Trust (since 2003) and Adjunct Professor at the Centre for Cancer Biomarkers at University of Bergen. He was previously Head of Medical Oncology, Director of the Ovarian Cancer Action Research Centre and Head of Imperial College Cancer Clinical Trials Unit, as well as Chief of Service of the West London Gynaecological Cancer Centre at Imperial College London. Prior to that he was Cancer Research UK Clinical Scientist and Honorary Clinical Senior Lecturer/Consultant in Medical Oncology at the CRUK Medical Oncology Unit in the University of Edinburgh.

Prof Gabra is an internationally recognised leader in translational research and gynaecological oncology. His research interests include tumour suppressor genes that regulate receptor tyrosine kinase networks (including AXL), the molecular basis of clinical platinum resistance, and all phases of ovarian cancer clinical research. He is the author of more than 200 peer reviewed publications and patents, with over 15,000 citations associated with his publications.

 .

Kwatsi is the company behind HealthPad.

Kwatsi is an innovative health knowledge network that combines the best of blogging and social networking with a micro transaction marketplace.

Kwatsi launched into public beta at the end of January 2012 with an amazing video library on gynaecologic cancers uploaded by experts, patients and students. Kwatsi has a rapidly growing community of users interested in health, lifestyle, medicine, fitness, nutrition and education. Start discovering, sharing and connecting with people around the world snd join our mission to make knowledge sharing rewarding and universally accessible.